Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Inclusion Criteria

• •Patients chronically infected with hepatitis C virus (HCV) genotype 1 or 4
• •HCV RNA viral load of ≥100,000 IU/mL
• •No previous exposure to interferon, pegIFNα, or RBV
• •Results of a liver biopsy demonstrating absence of cirrhosis obtained ≤24 months prior to randomization. Compensated cirrhotics with Hepatitis C virus genotype 1 infection are eligible, but will be capped at 10% of the randomized study population (biopsy can be from any time period prior to randomization)
• •Findings on ultrasound, computed tomography scan, or magnetic resonance imaging 12 months prior to randomization that do not demonstrate evidence of hepatocellular carcinoma
• •Body mass index of 18 to 35 kg/m\^2